Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monique Nilsson

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancerJohn V Heymach, Monique Nilsson, George Blumenschein, et al.
Molecular Cancer Therapeutics|February 5, 2008
Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endotheliumPaul Beaudry, Monique Nilsson, Matthew Rioth, et al.
NPJ Precision Oncology|October 1, 2024
Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patientsLingzhi Hong, Sonia Patel, Leylah M Drusbosky, et al.
Cancer Research|March 15, 2014
Tumor endothelial markers define novel subsets of cancer-specific circulating endothelial cells associated with antitumor efficacyReza Mehran, Monique Nilsson, Mehrdad Khajavi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 23, 2020
Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLCXiuning Le, Monique Nilsson, Jonathan Goldman, et al.
Plos One|April 8, 2016
Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung CancerRobert J Cardnell, Ying Feng, Seema Mukherjee, et al.
Oncotarget|July 8, 2016
Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutationsYuehong Wang, Ratnakar Singh, Liguang Wang, et al.
Lung Cancer (Amsterdam, Netherlands)|September 21, 2020
Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancerXiaoke Liu, Lingzhi Hong, Monique Nilsson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 10, 2018
Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural MesotheliomaAnne S Tsao, Heather Lin, Brett W Carter, et al.
The Journal of Biological Chemistry|September 5, 2021
Inhibition of nonsense-mediated decay rescues p53β/γ isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancersJayanthi P Gudikote, Tina Cascone, Alissa Poteete, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancerJohn V Heymach, Monique Nilsson, George Blumenschein, et al.
Molecular Cancer Therapeutics|February 5, 2008
Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endotheliumPaul Beaudry, Monique Nilsson, Matthew Rioth, et al.
NPJ Precision Oncology|October 1, 2024
Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patientsLingzhi Hong, Sonia Patel, Leylah M Drusbosky, et al.
Cancer Research|March 15, 2014
Tumor endothelial markers define novel subsets of cancer-specific circulating endothelial cells associated with antitumor efficacyReza Mehran, Monique Nilsson, Mehrdad Khajavi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 23, 2020
Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLCXiuning Le, Monique Nilsson, Jonathan Goldman, et al.
Plos One|April 8, 2016
Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung CancerRobert J Cardnell, Ying Feng, Seema Mukherjee, et al.
Oncotarget|July 8, 2016
Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutationsYuehong Wang, Ratnakar Singh, Liguang Wang, et al.
Lung Cancer (Amsterdam, Netherlands)|September 21, 2020
Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancerXiaoke Liu, Lingzhi Hong, Monique Nilsson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 10, 2018
Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural MesotheliomaAnne S Tsao, Heather Lin, Brett W Carter, et al.
The Journal of Biological Chemistry|September 5, 2021
Inhibition of nonsense-mediated decay rescues p53β/γ isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancersJayanthi P Gudikote, Tina Cascone, Alissa Poteete, et al.
Pageof 2